Is INSM a Buy? What to Consider in 2026
Short answer
The bull case for Insmed Incorporated (INSM) rests on BRINSUPRI as a potential blockbuster in a first-mover market: Brinsupri is the first and only approved treatment for non-cystic fibrosis bronchiectasis in the United States, European Union, and United Kingdom. Full-Year 2025 Revenue is ~$606 million. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. Whether INSM is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Insmed Incorporated (Nasdaq: INSM) is a Bridgewater, New Jersey-based global biopharmaceutical company focused on serious and rare diseases, organized across three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. Its commercial portfolio consists of two products. ARIKAYCE (amikacin liposome inhalation suspension) is an inhaled antibiotic approved in the United States, European Union, and Japan for refractory Mycobacterium avium complex (MAC) lung disease, a rare, chronic, and potentially fatal bacterial infection of the lungs. BRINSUPRI (brensocatib), a once-daily oral DPP1 inhibitor licensed from AstraZeneca in 2016, received FDA approval in August 2025 and European Commission approval in November 2025 as the first and only dedicated treatment for non-cystic fibrosis bronchiectasis, a progressive condition affecting an estimated 500,000 people in the United States alone. The pipeline includes TPIP, an inhaled treprostinil prodrug in Phase 3 development for pulmonary hypertension indications, as well as early-stage gene therapy programs in Duchenne muscular dystrophy and ALS. The company generates revenue entirely from product sales; it does not pay a dividend and remains net unprofitable as it invests heavily in commercial launches and clinical development. Insmed was founded in 1988 and spent its early years as a general biologics company before pivoting to focus on rare respiratory diseases. ARIKAYCE received its first U.S. approval in 2018 after a long development history involving inhaled liposomal delivery technology. The brensocatib acquisition in 2016 for $30 million upfront proved transformative: Phase 3 ASPEN trial data in 2024 sent the stock sharply higher and underpinned the 2025 FDA approval. Will Lewis has served as Chair and Chief Executive Officer and described 2025 as a turning point in which the company translated scientific advances into commercial execution. As of year-end 2025, Insmed employed approximately 1,660 people, up roughly 31% year-over-year, reflecting the build-out required for a two-product commercial infrastructure across the United States, Europe, and Japan.
What's the case for buying INSM?
BRINSUPRI as a potential blockbuster in a first-mover market
Brinsupri is the first and only approved treatment for non-cystic fibrosis bronchiectasis in the United States, European Union, and United Kingdom. The Phase 3 ASPEN trial enrolled more than 1,700 patients and showed statistically significant reductions in annualized pulmonary exacerbations versus placebo. With list pricing around $88,000 per year, no boxed warnings in the prescribing label, and roughly 9,000 new patients initiating treatment in Q4 2025 alone, analysts have projected peak U.S. sales could approach $3.7 billion by 2031.
ARIKAYCE growth and label expansion potential
ARIKAYCE delivered approximately $425 million in full-year 2025 global revenue, reflecting consistent double-digit annual growth across the United States, Europe, and Japan. The Phase 3b ENCORE study met its primary and all multiplicity-controlled secondary culture conversion endpoints in early 2026, supporting a planned supplemental NDA filing in the second half of 2026 that could expand the label to newly diagnosed MAC lung disease patients, a substantially larger addressable population than the current refractory indication.
TPIP pipeline optionality in pulmonary hypertension
TPIP (treprostinil palmitil inhalation powder) is an inhaled dry-powder formulation being evaluated across multiple pulmonary hypertension settings, including PH-ILD, PAH, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. The Phase 3 PALM-PAH study initiated in April 2026, and Phase 2b data in PAH showed a placebo-adjusted 35% reduction in pulmonary vascular resistance and a 35.5-meter improvement on the six-minute walk test. Positive Phase 3 outcomes across these indications would represent a third meaningful revenue franchise.
Approaching profitability on dual-product revenue scale
Q1 2026 net loss narrowed 36% year-over-year to $163.6 million as total revenues surged 230% to $306.0 million. Analyst consensus projects the company to reach profitability around 2028, with forecast earnings of approximately $742 million that year. Revenue is expected to grow at roughly 34% annually over the next three years, well above the broader biotech industry forecast, as BRINSUPRI matures and ARIKAYCE expands.
What are the risks to INSM?
The stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. Pipeline execution risk is real: brensocatib failed its Phase 2b BiRCh study in chronic rhinosinusitis without nasal polyps in December 2025, demonstrating that indication expansion is not guaranteed. The company continues to operate at a net loss and has relied on equity offerings, including a $750 million share sale in June 2025, to fund its commercial and clinical build-out, creating ongoing dilution risk. Royalty obligations to AstraZeneca on BRINSUPRI sales and restrictive covenants in its debt and royalty financing agreements add financial complexity.
How is INSM valued? (as of 2026-06-25)
- Full-Year 2025 Revenue: ~$606 million
- Q1 2026 Revenue (most recent quarter): ~$306 million
- 2026 Revenue Guidance (BRINSUPRI alone): at least $1 billion
- Net Loss per Share (Q1 2026): -$0.76
- Market Capitalization: ~$23.4 billion
- Price-to-Sales (trailing): ~26x
- Cash and Marketable Securities (March 31, 2026): ~$1.2 billion
- Dividend Yield: None
Insmed does not yet report a meaningful P/E ratio because the company remains net unprofitable, investing heavily in the BRINSUPRI commercial launch and clinical pipeline. Revenue growth is accelerating sharply: Q1 2026 revenues of $306 million exceeded Q1 2025 revenues of $92.8 million by more than 230%, driven by BRINSUPRI reaching $207.9 million in only its second full quarter on the market. The elevated price-to-sales multiple reflects market expectations that BRINSUPRI will scale toward blockbuster status, and investors are effectively paying a premium for a company that analysts do not expect to reach consensus profitability until approximately 2028.
How do you decide if INSM is a buy?
Rather than asking whether INSM is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold INSM indirectly through an index or sector ETF before adding more.
For the full picture, see the INSM stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about INSM against your real portfolio and see your actual exposure before deciding.
The bottom line on INSM
The bottom line: Insmed Incorporated's story right now is BRINSUPRI as a potential blockbuster in a first-mover market, with full-year 2025 revenue at ~$606 million. If you believe that narrative continues, the call is about sizing INSM sensibly and checking overlap with what you own; if you doubt it (the risk: the stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around INSM with Walnut
Use Insmed Incorporated as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is INSM a good stock to buy right now?
+
The case for Insmed Incorporated right now is BRINSUPRI as a potential blockbuster in a first-mover market, with full-year 2025 revenue at ~$606 million. If you believe that thesis holds, INSM is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Insmed Incorporated do?
+
Insmed Incorporated (Nasdaq: INSM) is a Bridgewater, New Jersey-based global biopharmaceutical company focused on serious and rare diseases, organized across three therapeutic area
What are the main risks of INSM?
+
The stock carries a demanding valuation, trading at roughly 26x trailing price-to-sales as of late June 2026, a meaningful premium to biotech peers, which means any shortfall in BRINSUPRI uptake or payer coverage could trigger sharp multiple compression. Pipeline execution risk is real: brensocatib failed its Phase 2b BiRCh study in chronic rhinosinusitis without nasal polyps in December 2025, demonstrating that indication expansion is not guaranteed. The company continues to operate at a net loss and has relied on equity offerings, including a $750 million share sale in June 2025, to fund its commercial and clinical build-out, creating ongoing dilution risk. Royalty obligations to AstraZeneca on BRINSUPRI sales and restrictive covenants in its debt and royalty financing agreements add financial complexity.
What does Insmed do?
+
Insmed is a global biopharmaceutical company focused on serious and rare respiratory diseases. It markets two products: ARIKAYCE, an inhaled antibiotic for refractory MAC lung disease approved in the U.S., EU, and Japan, and BRINSUPRI (brensocatib), the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis, which launched in August 2025. Its pipeline includes TPIP for pulmonary hypertension and early-stage gene therapy programs.
Is INSM a good stock to buy right now?
+
That depends on your risk tolerance and time horizon. INSM offers genuine commercial momentum: BRINSUPRI generated $207.9 million in Q1 2026 alone, with company guidance of at least $1 billion for the full year. However, the stock trades at roughly 26x trailing sales, the company is still unprofitable, and a recent pipeline failure in rhinosinusitis showed that expansion is not guaranteed. Whether the current price adequately reflects those risks is a judgment each investor must make for themselves.
Does INSM pay a dividend?
+
No. Insmed does not pay a dividend and has not announced plans to initiate one. The company continues to report net losses as it invests in the commercial launch of BRINSUPRI and its clinical pipeline. Investors are primarily exposed to potential capital appreciation, not income, and the company has funded operations in part through equity offerings, which can dilute existing shareholders.
Who are Insmed's main competitors?
+
In non-CF bronchiectasis, no other drug is currently approved in the U.S., though Merck's Verona Pharma asset Ohtuvayre is in development for the indication. In MAC lung disease, ARIKAYCE competes mainly with guideline-based antibiotic combinations. In pulmonary hypertension, where Insmed's TPIP pipeline is headed, established players include United Therapeutics, Johnson and Johnson, and GSK with multiple marketed therapies.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell INSM; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.